-22.1%
PYPL vs GSK
+24.6%
-46.6%
-48.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +0.2% | -2.1% | -1.9% |
| 7D | -4.3% | -3.6% | -0.7% | -4.4% |
| 30D | -11.5% | -5.9% | -5.5% | -11.5% |
| 3M | +26.1% | -4.3% | +30.4% | +26.2% |
| 6M | +13.7% | -10.8% | +24.5% | +13.0% |
| YTD | -9.8% | +1.8% | -11.6% | -9.6% |
| 1Y | -22.1% | +23.5% | -45.5% | -19.2% |
| All | -22.1% | +24.6% | -46.6% | -19.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling